Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Rating of “Hold” from Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $2.00.

A number of research analysts recently commented on the company. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, August 11th.

Heron Therapeutics Trading Up 13.5%

Shares of HRTX stock opened at $0.36 on Friday. Heron Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.57. The company has a debt-to-equity ratio of 24.35, a quick ratio of 1.51 and a current ratio of 2.49. The firm has a market capitalization of $67.57 million, a PE ratio of -1.87 and a beta of 1.62. The stock has a fifty day simple moving average of $0.36 and a two-hundred day simple moving average of $0.59.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter. The business had revenue of $37.67 million for the quarter, compared to the consensus estimate of $42.19 million. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. On average, analysts predict that Heron Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd bought a new position in shares of Heron Therapeutics during the 1st quarter valued at about $27,000. HORAN Wealth LLC bought a new stake in shares of Heron Therapeutics in the first quarter worth about $33,000. Ieq Capital LLC bought a new stake in shares of Heron Therapeutics in the second quarter worth about $41,000. Deutsche Bank AG purchased a new stake in shares of Heron Therapeutics in the second quarter worth about $41,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Heron Therapeutics by 335.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 35,106 shares of the biotechnology company’s stock worth $46,000 after buying an additional 27,040 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology. The company uses its Biochronomer drug-delivery platform to formulate therapies intended to provide sustained drug release and improve treatment convenience, efficacy, or tolerability.

Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain. The company also markets APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting in adults.